The Clinical Study On Procalcitonin Guidance For Antibiotic Use In Non-severe Community-acquired Pneumonia

ObjectiveTo evaluate the clinical value of serum procalcitonin level on guidance for antibiotic use in Non-severe community-acquired pneumoniaMethods60Patients with non-severe community-acquired pneumonia which the serum PCT were≥0.25ng/ml and<0.5ng/ml were randomized into Oral administration group (n=30)and intravenous group (n=30). The Oral administration group were treated with oral administration levofloxacin0.4g once a day for7-14day. The intravenous group were treated with levofloxacin0.4g intravenously once a day for7day..In both groups the observation of curative effects and costs were conducted.ResultsAfter treatment,compared with1st day,the levels of PCT declined significant in both group.The curative rate of the oral administration group and the intravenous group were66.7%and83.3%respectively, and there were no significant differences in results between the two groups of treatment(P>0.05). The effective rate of the oral administration group and the intravenous group were83.3%and90.0%respectively, and there were no significant differences in results between the two groups of treatment(P>0.05). The expense of antibiotics use in oral administration group and intravenous group were32yuan and462yuan respectively, which was significant difference between two groups.ConclusionsThe oral administration therapy was economic, safe and effective in treatment of non-severe community-acquired pneumonia, which the serum PCT were>o.25ng/ml and<0.5ng/ml.